



## Summit Therapeutics to Present Breakthrough Research Updates at the 31<sup>st</sup> Annual ECCMID Conference, including a Top-Rated ePoster

Cambridge, MA, July 1, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) (the "Company") today announced that members of our scientific team will present breakthrough research updates at the 31<sup>st</sup> European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will be held virtually July 9 – 12. Our three posters to be presented are as follows, one of which was designated as a Top Rated ePoster by the ECCMID conference:

- *ECCMID Top Rated ePoster*: Metagenomic Analysis of the Impact of the Precision Antibiotic Ridinilazole, Compared to Vancomycin, on the Gut Resistome in a Phase II Study
- Metagenomic Analysis of the Differential Impact of Ridinilazole and Vancomycin on the Gut Microbiota in a Phase II Study
- Identification of the Mechanism of Action for Ridinilazole, a Phase III Antibiotic for Treatment of *Clostridioides difficile*

Ridinilazole is our investigational drug currently in Phase III Ri-CoDIFy clinical trials with the goal of use as first-line therapy to treat initial infection and reduce recurrence of *Clostridioides difficile* infection.

*Clostridioides difficile*, or *C. difficile*, infection (CDI) is highly infectious disease that affects over 500,000 patients in the United States each year with approximately 25% of initial cases resulting in recurrent infections. Along with emotional and physical suffering, symptoms include inflammation of the colon, severe watery diarrhea, painful abdominal cramping, nausea, fever, dehydration, and in more severe cases, bowel perforation and sepsis. CDI is responsible for an estimated 20,000 to 30,000 deaths in the US each year with annual acute care costs estimated to be \$5.4 billion. Dysbiosis (dysfunction) of the gut microbiota is a major risk factor for initial instances of and recurrence of the disease.

Upon the completion of the conference, each poster will be available within the "Scientific Literature & Publications" section of our website: <https://www.summittxinc.com/publications/>.



### **About Summit Therapeutics**

The overriding objective of Summit Therapeutics is to create value for patients, hospital caregivers, and community-based healthcare providers, as well as healthcare payers around the world. We seek to create value by developing drugs with high therapeutic efficacy - curing the cause of the patient's condition with minimal or zero disease recurrence or antimicrobial resistance, for the longest extent possible - and minimizing the trauma caused to the patient and healthcare ecosystem by minimizing serious side effects, disease recurrence, and inaccessibility to our treatments as a result of financial or other barriers. Summit Therapeutics, empowered by its Discuva Platform, the Company's innovative antibiotic discovery engine, supported by BARDA and CARB-X funding, intends to be the leader in patient-friendly and paradigm-shifting treatments for infectious diseases and other significant unmet medical needs while being an ally to physicians. Our new mechanism pipeline product candidates are designed with the goal to become the patient-friendly, new-era standard of care, by working in harmony with the human microbiome to treat prospective patients suffering from infectious disease, initially focusing on *Clostridioides difficile* infections (CDI). Currently, Summit's lead product candidate, ridinilazole, is engaged in two pivotal global Phase III trials, Ri-CoDIFy 1 & 2, each enrolling approximately 680 patients vs. the standard of care (vancomycin) for the treatment and reduction of recurrence of *C. difficile* infections, in addition to an adolescent trial, Ri-CoDIFy 3. Commercialization of ridinilazole for the treatment and the reduction of recurrence of CDI is subject to regulatory approvals. SMT-738, the second candidate within Summit's portfolio, is currently in the IND-enabling phase for the treatment of multidrug resistant infections, specifically those caused by carbapenem-resistant Enterobacteriaceae (CRE).

For more information, please visit <https://www.summittxinc.com> and follow us on Twitter @summitplc. For more information on the Company's Discuva Platform, please visit <https://www.summittxinc.com/our-science/discuva-platform>.

### **About *C. difficile* Infection**

*C. difficile* infection is a bacterial infection of the colon that produces toxins causing inflammation of the colon and severe watery diarrhea, painful abdominal cramping, nausea, fever, and dehydration. CDI is highly contagious and can also result in more serious disease complications, including bowel perforation, sepsis, and death. CDI is a contagious infectious disease that represents a serious healthcare issue in hospitals, long-term care homes, and the wider community. Summit estimates that there are approximately 500,000 cases of CDI each year across the United States based on a meta-analysis published in the *Journal of Global Health*, June 2019.

### **Contact Summit Investor Relations**

Dave Gancarz  
Head of Investor Relations & Corporate Strategy  
[david.gancarz@summitplc.com](mailto:david.gancarz@summitplc.com)

General Inquiries:  
[investors@summitplc.com](mailto:investors@summitplc.com)



### **Summit Forward-looking Statements**

Any statements in this press release about the Company's future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company's product candidates, the therapeutic potential of the Company's product candidates, the potential commercialization of the Company's product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the impact of the COVID-19 pandemic on the Company's operations and clinical trials and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, global public health crises, including the coronavirus COVID-19 outbreak, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing the Company's views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.